Using molecular knockdown and ibrutinib, we demonstrated that the inhibition of BTK signaling markedly reduces the subpopulation of CSCs and enhances the anticancer effects of conservative chemotherapy in ovarian and GBM cancer cells [18,19]. The gene discussed is BTK; the disease is glioblastoma.